通过试验证实了微珠在很高的压力下仍然完好，其密度增加是由于水被压入部分具有较大孔径的微珠中所致。
In this paper, it is proven by testing result that the fine-grains could be in good condition even under great pressure.
CATT研究结果支持全球继续使用玻璃体腔入路的给药途径使用倍伐单抗作为对雷珠单抗的一种廉价选择。
The CATT data support the continued global use of intravitreal bevacizumab as an effective. low-cost alternative to ranibizumab, particularly for patients paying all costs out of pocket.
应用推荐